These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8747511)

  • 1. Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules.
    Fabris C; Falleti E; Pirisi M; Soardo G; Toniutto P; Vitulli D; Bortolotti N; Gonano F; Bartoli E
    Clin Chim Acta; 1995 Dec; 243(1):25-33. PubMed ID: 8747511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Cervello M; Virruso L; Lipani G; Giannitrapani L; Soresi M; Carroccio A; Gambino R; Sanfililippo R; Marasà L; Montalto G
    J Cancer Res Clin Oncol; 2000 Jun; 126(6):345-51. PubMed ID: 10870645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating standard CD44 isoform in patients with liver disease: relationship with other soluble adhesion molecules and evaluation of diagnostic usefulness.
    Falleti E; Pirisi M; Fabris C; Bortolotti N; Soardo G; Gonano F; Bartoli E
    Clin Biochem; 1997 Feb; 30(1):69-73. PubMed ID: 9056113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis.
    Zöhrens G; Armbrust T; Pirzer U; Meyer zum Büschenfelde KH; Ramadori G
    Hepatology; 1993 Oct; 18(4):798-802. PubMed ID: 8104856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CA 125 as a serum marker of hepatocellular carcinoma.
    Elias J; Kew MC
    Int J Cancer; 1990 Nov; 46(5):805-7. PubMed ID: 2172170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis.
    Giannini E; Borro P; Botta F; Chiarbonello B; Fasoli A; Malfatti F; Romagnoli P; Testa E; Risso D; Lantieri PB; Antonucci A; Boccato M; Milone S; Testa R
    Int J Biol Markers; 2000; 15(3):226-30. PubMed ID: 11012098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Soluble cell adhesion molecules in chronic renal graft rejection].
    Boratyńska M
    Pol Arch Med Wewn; 1998 Nov; 100(5):410-8. PubMed ID: 10410574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes.
    Thomson AW; Satoh S; Nüssler AK; Tamura K; Woo J; Gavaler J; van Thiel DH
    Clin Exp Immunol; 1994 Jan; 95(1):83-90. PubMed ID: 7904546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular adhesion molecule-1 release from human hepatocellular carcinoma.
    Hyodo I; Jinno K; Tanimizu M; Doi T; Nishikawa Y; Hosokawa Y; Moriwaki S
    Cancer Detect Prev; 1996; 20(4):308-15. PubMed ID: 8818391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases.
    Pirisi M; Fabris C; Falleti E; Soardo G; Toniutto P; Vitulli D; Gonano F; Bartoli E
    Dis Markers; 1996 Aug; 13(1):11-7. PubMed ID: 8875114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease.
    Puoti C; Bellis L; Guarisco R
    Dig Liver Dis; 2010 May; 42(5):387. PubMed ID: 19181575
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass.
    Pirisi M; Falleti E; Fabris C; Soardo G; Toniutto P; Vitulli D; Pezzetta F; Bortolotti N; Gonano F; Bartoli E
    Am J Clin Pathol; 1994 Nov; 102(5):600-4. PubMed ID: 7942624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma.
    Zhang J; Huang T; Zhang F; Xu J; Chen G; Wang X; Huang L; Peng Z
    Tumour Biol; 2015 Apr; 36(4):2257-61. PubMed ID: 25787748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease.
    Fabris C; Pirisi M; Panozzo MP; Soardo G; Toniutto P; Hocza V; Bartoli E
    J Clin Pathol; 1993 Apr; 46(4):364-7. PubMed ID: 8388408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.
    Murawaki Y; Yamamoto H; Kawasaki H; Shima H
    Clin Chim Acta; 1993 Sep; 218(1):47-58. PubMed ID: 8299219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
    Huang YS; Wu JC; Chan CY; Chao Y; Chang FY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug; 62(8):487-95. PubMed ID: 10462824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagen-binding activity of plasma vitronectin in chronic liver disease.
    Yamada S; Kobayashi J; Murawaki Y; Suou T; Kawasaki H
    Clin Chim Acta; 1996 Aug; 252(1):95-103. PubMed ID: 8814365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis.
    Simpson KJ; Jones AL; Forbes Howie A; Hayes PC
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):455-60. PubMed ID: 7542148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
    Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
    J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
    Nowak J; Jakubowska D; Wiczkowski A; Sprzaczkowska K; Stechły T; Zmudziński W; Grzesik P; Walas R; Jarzab B
    Wiad Lek; 1998; 51(11-12):484-91. PubMed ID: 10222840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.